Stephen Gardner to Liver Cirrhosis
This is a "connection" page, showing publications Stephen Gardner has written about Liver Cirrhosis.
Connection Strength
0.348
-
Fibrogenesis assessed by serological type III collagen formation identifies patients with progressive liver fibrosis and responders to a potential antifibrotic therapy. Am J Physiol Gastrointest Liver Physiol. 2016 12 01; 311(6):G1009-G1017.
Score: 0.110
-
Plasma Pro-C3 (N-terminal type III collagen propeptide) predicts fibrosis progression in patients with chronic hepatitis C. Liver Int. 2015 Feb; 35(2):429-37.
Score: 0.096
-
Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infection. Gastroenterology. 2010 Apr; 138(4):1365-73, 1373.e1-2.
Score: 0.069
-
A United States compassionate use study of lamivudine treatment in nontransplantation candidates with decompensated hepatitis B virus-related cirrhosis. Liver Transpl. 2003 Jan; 9(1):49-56.
Score: 0.042
-
Pleiotropy and allelic heterogeneity in the TOMM40-APOE genomic region related to clinical and metabolic features of hepatitis C infection. Hum Genet. 2012 Dec; 131(12):1911-20.
Score: 0.021
-
Histological outcome during long-term lamivudine therapy. Gastroenterology. 2003 Jan; 124(1):105-17.
Score: 0.011